Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Silvia Martini
Institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
ORCID:
0000-0001-9314-5230
Observed ORCID:
0000-0001-9314-5230
OpenAlex ID:
A5070346116
Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer
2019
·
Angelo Spinello
, Silvia Martini
, et al.
·
European Journal of Medicinal Chemistry
·
37
PDF
Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer
2021
·
Jessica Caciolla
, Silvia Martini
, et al.
·
European Journal of Medicinal Chemistry
·
31
PDF
Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors
2020
·
Jessica Caciolla
, Angelo Spinello
, et al.
·
ACS Medicinal Chemistry Letters
·
23
miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer
2021
·
Silvia Martini
, Valentina Zuco
, et al.
·
Pharmaceuticals
·
16
PDF
Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
2020
·
Silvia Martini
, Mariangela Figini
, et al.
·
Cells
·
16
PDF
Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment
2023
·
Silvia Gobbi
, Silvia Martini
, et al.
·
Molecules
·
15
PDF
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
·
Clinical Cancer Research
·
13
miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma
2022
·
Rihan El Bezawy
, Stefano Percio
, et al.
·
Cancer Gene Therapy
·
11
PDF
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer
2022
·
Carlotta Antoniotti
, Federica Marmorino
, et al.
·
European Journal of Cancer
·
10
Single-digit nanomolar inhibitors lock the aromatase active site via a dualsteric targeting strategy
2022
·
Jessica Caciolla
, Silvia Martini
, et al.
·
European Journal of Medicinal Chemistry
·
7
Abstract 6552: ZEB1-AS1 lncRNA prevents ZEB1 suppression and leads to tumor progression in undifferentiated AML subtype
2023
·
Stefano Percio
, Daniela Magliulo
, et al.
·
Cancer Research
·
2
Abstract B011: GDF-15 is a biomarker of aggressiveness in epithelioid hemangioendothelioma and is down-regulated by sirolimus through ATF4 suppression
2023
·
Alessia Beretta
, Valentina Zuco
, et al.
·
Molecular Cancer Therapeutics
·
1
FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
2026
·
Valentina Doldi
, Chiara Maura Ciniselli
, et al.
·
Journal of Translational Medicine
Data from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Figure 3 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Supplementary Figure 4 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Figure 1 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Supplementary Figure 10 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Supplementary Figure 3 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Figure 5 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Figure 2 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Figure 4 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Supplementary Figure 1 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Supplementary Figure 2 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Supplementary Figure 7 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
2024
·
Silvia Stacchiotti
, Silvia Martini
, et al.
Show more works
View as search
Works count:
40
Citation count:
182
H-index:
9
I10-index:
9
Year
Topic
Type
